(2,4-Dichloro-5-isopropoxyphenyl)hydrazine | CAS:40178-22-1

We serve (2,4-Dichloro-5-isopropoxyphenyl)hydrazine CAS:40178-22-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
(2,4-Dichloro-5-isopropoxyphenyl)hydrazine

CAS No: 40178-22-1
Product Name: (2,4-Dichloro-5-isopropoxyphenyl)hydrazine
Other Name:
(2,4-Dichloro-5-isopropoxyphenyl)hydrazine
2,4-Dichloro-5-(1-methylethoxy)phenylhydrazine
 
Density: 1.325g/cm3
Boiling Point: 319.9ºC at 760mmHg
Molecular Formula: C9H12Cl2N2O
Molecular Weight: 235.11000
Flash Point: 147.3ºC
Exact Mass: 234.03300
PSA: 47.28000
LogP: 3.83950
Index of Refraction: 1.597
 
Specification
Appearance: White solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Oxadiazon CAS: 19666-30-9.
Be used as pesticide intermediate, mainly used in synthetic herbicide Oxadiazon.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.



Contact us for information like (2,4-Dichloro-5-isopropoxyphenyl)hydrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,4-Dichloro-5-(1-methylethoxy)phenylhydrazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2,4-Dichloro-5-(1-methylethoxy)phenylhydrazine Use and application,(2,4-Dichloro-5-isopropoxyphenyl)hydrazine technical grade,usp/ep/jp grade.


Related News: 1,4-Dichlorobutane manufacturer With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.L-Menthyl glyoxylate hydrate supplier With the speeding up of review and approval, the number of approved innovative drugs in China is about to usher in a year of blowout.3-Amino-2-Chlor-6-Methylphenol vendor Drug manufacturers make medicines by mixing APIs and pharmaceutical excipients.Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK.